Stubborn Valeant powers ahead with extended Allergan buyout offer

Valeant's ($VRX) tender offer for Allergan ($AGN) isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan. At least one supporter is betting heavily that the Canadian pharma can pull the deal off: Paulson & Co. acquired 5.6 million shares of Allergan valued at nearly $1 billion during the second quarter, Bloomberg reports. News (sub. req.) | More

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.